Foundayo: cost, evidence, and the honest comparison

Orforglipron targets the same GLP-1 receptor as the injectables, but as a small molecule rather than a peptide — which is why it can be swallowed without the food-and-water timing rules that oral semaglutide requires.

What it's approved for

Chronic weight management in adults, approved April 2026 — the first small-molecule GLP-1 pill in the class.

Forms and doses: Once-daily tablet, 0.8 mg through 17.2 mg, taken any time of day with no food or water restrictions.

What the research actually shows

Approved through the FDA's National Priority Voucher pathway in April 2026 on the strength of its phase 3 programme. Because it launched recently, long-term real-world data is still accumulating — worth knowing before assuming equivalence with older options.

Sources: Eli Lilly approval announcement, April 2026 · FDA National Priority Voucher programme

Side effects, stated plainly

Gastrointestinal effects consistent with the GLP-1 class were the most common in trials. As a recently approved medicine, its long-term safety picture is younger than semaglutide's or tirzepatide's.

What it costs

Launch pricing is aggressive at the entry doses — $149 to $349 a month by dose through the manufacturer's channel, with promotional tiers running through the end of 2026, and it is included in Medicare's $50 Bridge copay.

ChannelForm & doseMedRequired feeTrue monthlyStatus
LillyDirect — FoundayoLOWEST LISTED pill · 0.8 mg $149 $149 reported
LillyDirect — Foundayo pill · 2.5 mg $199 $199 reported
Hims & Hers pill · from $149 $149 $149/mo $298 listed
Ro (Ro Body) pill · 0.8 mg $149 $149/mo $298 listed
LillyDirect — Foundayo pill · 5.5 mg $299 $299 reported
LillyDirect — Foundayo pill · 9 mg $299 $299 reported
Ro (Ro Body) pill · 2.5/5.5 mg (promo) $199 $149/mo $348 listed
LillyDirect — Foundayo pill · 14.5 mg $349 $349 reported
LillyDirect — Foundayo pill · 17.2 mg $349 $349 reported
Ro (Ro Body) pill · 9 mg $299 $149/mo $448 listed

True monthly = medication plus any required membership fee. Cheapest listed right now: LillyDirect — Foundayo at $149/month. Full table and filters on the Foundayo cost page.

Keep reading

Common questions

How is Foundayo different from the Wegovy pill?

Both are once-daily GLP-1 tablets, but Foundayo is a small molecule with no food or water timing rules, while oral semaglutide must be taken on an empty stomach with specific water and waiting requirements. Prices differ by dose — both are on our cost pages.

Other weight loss medications

Wegovy · Zepbound · Ozempic · Compounded semaglutide · Compounded tirzepatide · Liraglutide

Foundayo market news

2026-07-29
FTC, Utah, and LA County sue Hims & Hers over health-data sharing and cancellation practices

The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.

The Hims dossier →
2026-07-01
Medicare's $50/month GLP-1 Bridge copay goes live

Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.

How the Bridge actually works →
2026-04-30
FDA moves to permanently end bulk compounding of semaglutide and tirzepatide

The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.

The surviving market, explained →

All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.

Educational and pricing journalism, not medical advice — indications, dosing, and suitability are decisions for you and a licensed clinician, and the FDA label is the authority on risks. Prices carry the verification dates shown; the provider's checkout is the final word. Some links may earn commissions; rankings are ordered by cost, never compensation — disclosure.

Prices here change monthly. Get one email when they do. Free price-drop alerts →